Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses the application frequency of Koshine 1% for hair loss, with conflicting instructions between Amazon and the main website. The user is unsure whether to apply it once or twice daily.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

Switching from ketoconazole to a ciclopirox and zinc pyrithione shampoo significantly reduced hair fall. The user is considering whether to continue using ketoconazole occasionally or combine both shampoos weekly.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Twist-1 is being explored as a promising early-stage hair loss treatment, while Scube-3's effect on Twist-1 in breast cancer cells raises concerns about its use for hair loss. The conversation discusses the potential differences in protein effects across various cell types.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

The conversation discusses skepticism about the effectiveness of PP405 for hair loss, with users mentioning treatments like dutasteride, oral minoxidil, clascoterone, and upcoming drugs like breezula and long-release oral minoxidil. Some users express hope for future treatments like vdphl01 and amplifica, while others debate the effectiveness and side effects of current options.

A user has been taking finasteride for 7 months and is experiencing watery semen as the only side effect. They are considering taking zinc supplements to improve this condition.

OP used HIMS hybrid tablets containing 1.1mg finasteride, 3mg minoxidil, and 2.5mg biotin, showing significant hair regrowth after initial shedding. OP experienced no side effects and plans to continue treatment.

Everychem's solution, similar to PP405, has mixed results for hair regrowth, with some users reporting improvements and others seeing no change or worsening hair loss. Users are sharing experiences and updates to determine its effectiveness.

The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.

A user discusses using Alpecin Caffeine Liquid for scalp health and considers dissolving finasteride tablets into it for a DIY topical treatment. They inquire about potential absorption issues with this method.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

The conversation is about using Winlevi 1% cream, Pyri (Koshine) 0.5%, and minoxidil for hair loss treatment. The user is hopeful for results with Winlevi but is sensitive to 5AR blockers.

The user achieved impressive hair regrowth using 1mg finasteride and topical minoxidil, and is now adding dutasteride due to recent diffuse thinning. They experienced initial side effects with finasteride but no longer have issues.

The conversation humorously discusses the use of pp405 for hair loss, with mentions of finasteride and minoxidil. Users joke about unusual side effects like growing extra body parts.

The user shared progress pictures after 5 months of using 1mg finasteride, weekly 1.5mm microneedling, and daily 2mg copper peptide injections. They discussed their hair loss treatment and results.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.